FDA Approvals
On June 12, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Learn More
On June 13, 2024, the Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company).
Learn More
On June 14, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
Learn More
On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
Learn More
On June 21, 2024, the Food and Drug Administration granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc., a Bristol Myers Squibb company) plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).
Learn More
On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Learn More
FDA LINK
Learn More
National Guideline Updates
The National Comprehensive Cancer Network (NCCN) is seeking community oncology practices to participate in the Health Equity Report Card Pilot Project in Community Oncology settings.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Endometrial Carcinoma and Uterine Sarcoma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uterine Neoplasms v2.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Non-Small Cell Lung Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v6.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Myeloproliferative Neoplasms to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms v1.2024.
Learn More
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Classic Follicular Lymphoma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas v2.2024.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma. These NCCN Guidelines® are currently available as Version 3.2024.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Small Cell Lung Cancer. These NCCN Guidelines®are currently available as Version 3.2024.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions. These NCCN Guidelines® are currently available as Version 2.2024.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 1.2024.
Learn More
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer. These NCCN Guidelines® are currently available as Version 7.2024.
Learn More
The NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer v6.2024 has been updated and published based on the most recent changes from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
Learn More
Coding and Reimbursement Updates
View E-Reimbursement Newsletter Here:
Learn More
Other
Noridian Medicare Jurisdiction E Part B
Learn More
California Medical Association Practices Resources (CPR):
Learn More
